Kenvue Inc. (NYSE:KVUE) Stock Position Cut by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 12.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 890,000 shares of the company’s stock after selling 130,000 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Kenvue were worth $19,002,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Townsquare Capital LLC lifted its position in Kenvue by 25.3% in the third quarter. Townsquare Capital LLC now owns 52,713 shares of the company’s stock worth $1,219,000 after purchasing an additional 10,629 shares during the period. Alerus Financial NA raised its stake in shares of Kenvue by 0.3% in the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after buying an additional 491 shares in the last quarter. Paloma Partners Management Co acquired a new stake in shares of Kenvue in the third quarter valued at $360,000. Benjamin Edwards Inc. acquired a new stake in shares of Kenvue in the third quarter valued at $1,323,000. Finally, Holocene Advisors LP boosted its stake in Kenvue by 75.5% during the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after buying an additional 5,975,392 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of research analyst reports. UBS Group cut their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Canaccord Genuity Group increased their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Evercore ISI initiated coverage on Kenvue in a report on Monday, March 24th. They issued an “in-line” rating and a $25.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Kenvue presently has a consensus rating of “Hold” and an average target price of $24.00.

Kenvue Stock Up 1.0 %

Shares of Kenvue stock opened at $23.74 on Monday. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a market cap of $45.36 billion, a P/E ratio of 44.78, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a 50-day moving average price of $22.32 and a 200 day moving average price of $22.45.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.45%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.